Novartis (United Kingdom)
In research, Novartis (United Kingdom) stands highest in Medicine (#4,513 of 17,978 worldwide), Life Sciences (#3,817 of 14,347 worldwide) and Health Sciences (#6,187 of 20,462 worldwide), over all time.
- World rank, all time
- #8,247 of 42,892
- Rank in United Kingdom
- #470 of 2,253
- Research works
- 567 ▼ 65% vs 2013–17
- Citations
- 26k 46.6 per fractional work
- Top-10% rate
- 12.1% record average 16.5%
- Open access
- 32% world 28%
What is Novartis (United Kingdom) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| MedicineField | #4,513 of 17,978 | 25.9% | 291 | |
| Life SciencesDomain | #3,817 of 14,347 | 31.0% | 180 | |
| Health SciencesDomain | #6,187 of 20,462 | 25.8% | 303 |
Each strip is that field’s whole ranked pool, with the notch where Novartis (United Kingdom) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 10.3×. Every wedge is a field page.
- Immunology and Microbiology 10.3×
- Economics, Econometrics and Finance 3.5×
- Medicine 3.4×
- Mathematics 1.8×
- Veterinary 1.7×
- Biochemistry, Genetics and Molecular Biology 1.4×
- Health Professions 0.7×
- Pharmacology, Toxicology and Pharmaceutics 0.5×
- Neuroscience 0.4×
- Chemistry 0.3×
- Business, Management and Accounting 0.2×
- Environmental Science 0.2×
- Decision Sciences 0.1×
- Computer Science 0.1×
- Psychology 0.1×
- Materials Science 0.1×
- Social Sciences 0.0×
Which keywords describe research at Novartis (United Kingdom)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Genetics, Clinical Trials, Innate Immunity, Regulation, Complement, Immune, Glomerular Diseases and Nephrotic Syndrome.
- Prognosis
- Cardiovascular Disease
- Blood Groups
- Alloimmunization
- Anemia
- Cost-effectiveness Analysis
- Hypercholesterolemia
- Cholesterol-lowering
- Genetic Variants
- Statins
- Nephrotic Syndrome
- Quality of Life
- Complement
- Innate Immunity
- Clinical Trials
- Genetics
- Epidemiology
- Regulation
- Immune
- Glomerular Diseases
- Inflammation
- Cardiovascular Disease Prevention
- Treatment
- Diagnosis
- LDL Cholesterol
- Health Utility Measures
- Pancreatic Cancer
- Autoantibodies
- Targeted Therapy
- Immune Response
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 30 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 30 words, with their numbers
- Genetics3▲ 12×6 topics
- Clinical Trials3▲ 12×8 topics
- Epidemiology3▲ 1.97×31 topics
- Innate Immunity2▲ 22×3 topics
- Regulation2▲ 13×2 topics
- Complement2▲ 394×1 topic
- Immune2▲ 394×1 topic
- Quality of Life2▲ 4.6×9 topics
- Glomerular Diseases2▲ 172×1 topic
- Nephrotic Syndrome2▲ 172×1 topic
- Inflammation2▲ 2.4×12 topics
- Statins2▲ 68×2 topics
- Cardiovascular Disease Prevention2▲ 54×2 topics
- Genetic Variants2▲ 27×2 topics
- Treatment2▲ 4.0×12 topics
- Cholesterol-lowering2▲ 99×1 topic
- Diagnosis2▲ 4.7×13 topics
- Hypercholesterolemia2▲ 106×2 topics
- LDL Cholesterol2▲ 129×1 topic
- Cost-effectiveness Analysis2▲ 51×1 topic
- Health Utility Measures2▲ 51×1 topic
- Anemia1▲ 41×3 topics
- Pancreatic Cancer1▲ 37×2 topics
- Alloimmunization1▲ 151×1 topic
- Autoantibodies1▲ 16×6 topics
- Blood Groups1▲ 151×1 topic
- Targeted Therapy1▲ 17×4 topics
- Cardiovascular Disease1▲ 2.7×9 topics
- Immune Response1▲ 5.3×6 topics
- Prognosis1▲ 9.1×6 topics
Which research topics does Novartis (United Kingdom) publish most on?
By volume in 2022–2025: Complement system in diseases, Renal Diseases and Glomerulopathies, Lipoproteins and Cardiovascular Health and Health Systems, Economic Evaluations, Quality of Life.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Complement system in diseases Immunology 2 works
- 2 Renal Diseases and Glomerulopathies Nephrology 2 works
- 3 Lipoproteins and Cardiovascular Health Surgery 2 works
- 4 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 2 works
- 5 Blood groups and transfusion Hematology 1 works
- 6 Chronic Myeloid Leukemia Treatments Hematology 1 works
- 7 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
- 8 Liver Disease and Transplantation Hepatology 1 works
- 9 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
- 10 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Novartis (United Kingdom)'s research output changed?
Output in 2018–2022 was 65% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Frimley
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.